Onconova grants SymBio exclusive rights in Japan and Korea to cancer candidate rigosertib (ON 01910.Na)

Onconova Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

SymBio Pharmaceuticals Ltd.

Japan / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced